Liraglutide and Semaglutide Tablets: How They Compare for Weight Loss

Step 1: Understand what liraglutide and oral semaglutide actually are

Both molecules belong to the GLP-1 receptor agonist class. They mimic a gut hormone that signals fullness, slows gastric emptying and reduces appetite. The resemblance stops there.

Liraglutide, sold as Saxenda for weight management and Victoza for type 2 diabetes, is injected once daily. It has a shorter half-life than semaglutide, which is why the daily injection is needed. Saxenda is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with a weight-related condition, alongside a reduced-calorie diet and increased physical activity.

Oral semaglutide for weight loss is a newer development. Semaglutide's half-life is long enough to sustain once-weekly injections (Wegovy, Ozempic) but, crucially, Novo Nordisk have also developed a tablet formulation that pairs semaglutide with an absorption enhancer called SNAC. This allows the medicine to cross the stomach wall into the bloodstream, something standard protein molecules cannot do without help. The result is the Wegovy tablet, which the MHRA approved on 11 June 2026 as the first oral GLP-1 medicine cleared for weight management in the UK.

The NHS medicines page on semaglutide covers the injectable forms in detail and is a reliable starting point for understanding the molecule's side-effect profile.

Step 2: Separate the licensed products from the ones that aren't licensed for weight loss

A question our prescribers hear most weeks is some version of: "Can I get the semaglutide tablet my friend mentioned, the one that isn't the injection?" The honest answer requires a short detour into branding.

Three oral semaglutide products exist or have been discussed in the UK context. Rybelsus comes in 3 mg, 7 mg and 14 mg tablets and is licensed exclusively for type 2 diabetes, not weight management. Ozempic is an injectable semaglutide for type 2 diabetes, not weight loss. Neither should be used outside their licensed indication. You can read more about how the brands differ on the semaglutide tablet brands page.

The only oral semaglutide product with a UK weight-management licence is Wegovy in tablet form: a dosing ladder of 1.5 mg rising through 4 mg and 9 mg to a 25 mg maintenance dose, taken once daily on an empty stomach, at least 30 minutes before food or other medicines. If you want a fuller picture of what semaglutide oral tablets involve, including how the SNAC absorption system works and what to expect from the dosing schedule, our dedicated page covers those details. Those Rybelsus strengths (3 mg, 7 mg, 14 mg) are a separate product for a separate condition, they are not steps on the Wegovy weight-loss ladder.

Liraglutide (Saxenda) sits in a different part of the picture entirely: a different molecule, a daily injection, and a product that has been on the UK market considerably longer. Comparing it with oral semaglutide is reasonable as a concept, but the clinical profiles are distinct enough that a prescriber needs to assess which is appropriate rather than a patient choosing between them on price or convenience alone.

Step 3: Look at what the evidence shows for each

Saxenda's phase-3 trials (the SCALE programme) showed average weight reductions of around 5–8% over 56 weeks at the 3 mg maintenance dose, alongside lifestyle changes. The trial population included adults with and without type 2 diabetes, and results varied by group.

For Wegovy tablets, the pivotal data come from the OASIS 4 trial, 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, over 64 weeks. Average weight loss was around 13.6% compared with approximately 2.4% for placebo, regardless of adherence. Among participants who stayed fully on treatment, the figure reached approximately 16.6%. The mechanism behind oral semaglutide explains why that absorption step is so critical to achieving those outcomes.

These figures cannot be directly cross-compared: different durations, different doses, different populations. What they do show is that oral semaglutide at 25 mg appears to produce meaningfully greater average losses than liraglutide in its own trial setting. A NICE appraisal of Wegovy tablets has not yet been published, so the longer-term NHS commissioning picture is still developing.

Step 4: Find out which medicines are actually available, and through which route

Saxenda (liraglutide) is not dispensed by nume. It is licensed for weight management in the UK, but it is not part of the treatments we offer. If Saxenda is relevant to your situation, your GP or a specialist service can advise.

What is available at nume, subject to clinical assessment, is oral semaglutide as Wegovy tablets, as well as Wegovy in its injectable form and Mounjaro (tirzepatide), which is a dual GIP and GLP-1 receptor agonist. All are prescription-only medicines; a GPhC-registered prescriber reviews every consultation before any treatment is issued. There are no subscriptions or auto-renewals, and every repeat order goes through the same clinical check.

For a broader look at the options available through our pharmacy, the weight-loss treatment overview sets out each medicine, how it works and who it may suit. Pricing context, including what a legitimate prescription service includes beyond the medicine itself, is covered on the treatment consultation page.

Both liraglutide and oral semaglutide tablets require clinical assessment before use, BMI alone does not determine suitability. History, current medicines, and any relevant conditions all shape the prescriber's decision. Our semaglutide tablets page goes into further detail on who may be suitable and what the prescribing process involves. Oral contraceptive users starting on semaglutide-class medicines should discuss their contraception with the prescriber, since absorption of the pill may be affected during treatment adjustments. Pregnancy, breastfeeding, and planning to conceive are reasons these medicines are not recommended; that applies to all GLP-1 products. Anyone under 18 falls outside the licensed age range for both.

If you have questions beyond what a page can answer, the general FAQs cover a wide range of common concerns, or you can contact the team directly. When you are ready to explore whether oral semaglutide is right for you, start your free consultation through the link below.